Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanxi Jinbo Bio pharmaceutical CoBJSE:920982 77 Cyclically Adjusted PB Ratio is 16.96 as of Sep. 15, 2026, which is 27% below its 10-year median of 23.35. GuruFocus rates BJSE:920982 with a GF Score™ of 77/100 and a GF Value™ of ¥235.87 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 680 Biotechnology companies, Shanxi Jinbo Bio pharmaceutical Co ranks worse than 91.32% on this metric.
Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Shanxi Jinbo Bio pharmaceutical Co Cyclically Adjusted PB Ratio Related Terms
Shanxi Jinbo Bio pharmaceutical Co Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Jinbo Bio pharmaceutical Co Cyclically Adjusted PB Ratio Chart
BJSE:920982 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Shanxi Jinbo Bio pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanxi Jinbo Bio pharmaceutical Co Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanxi Jinbo Bio pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Shanxi Jinbo Bio pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.
Shanxi Jinbo Bio pharmaceutical Co Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Shanxi Jinbo Bio pharmaceutical Co does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
What does a Cyclically Adjusted PB Ratio of 16.96 mean?
Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) has a Cyclically Adjusted PB Ratio of 16.96 as of Sep. 15, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Shanxi Jinbo Bio pharmaceutical Co and its competitors. This is 27% below median its historical median of 23.35. Over the past decade, Shanxi Jinbo Bio pharmaceutical Co's Cyclically Adjusted PB Ratio has ranged from 14.88 to 35.22. According to the industry distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #621 out of 680 companies in the Biotechnology industry, placing it in the top 91.3%.
Is Shanxi Jinbo Bio pharmaceutical Co's Cyclically Adjusted PB Ratio too high?
Shanxi Jinbo Bio pharmaceutical Co's current Cyclically Adjusted PB Ratio of 16.96 is 27% below median its 10-year median of 23.35. Over the past 10 years, this metric has ranged from a low of 14.88 to a high of 35.22. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.58. Shanxi Jinbo Bio pharmaceutical Co's value of 16.96 is 976.8% above this industry median. Based on the distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #621 out of 680 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanxi Jinbo Bio pharmaceutical Co has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanxi Jinbo Bio pharmaceutical Co's Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #621 out of 680 companies for Cyclically Adjusted PB Ratio. This places Shanxi Jinbo Bio pharmaceutical Co in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.58. Shanxi Jinbo Bio pharmaceutical Co's value of 16.96 is 976.8% above this benchmark. Historically, Shanxi Jinbo Bio pharmaceutical Co's own Cyclically Adjusted PB Ratio has ranged from 14.88 to 35.22 over the past decade. While the company's 10-year median is 23.35 vs. the industry median of 1.58, Shanxi Jinbo Bio pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.58, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanxi Jinbo Bio pharmaceutical Co's current Cyclically Adjusted PB Ratio of 16.96 is 976.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Shanxi Jinbo Bio pharmaceutical Co and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanxi Jinbo Bio pharmaceutical Co's current Cyclically Adjusted PB Ratio is 16.96, which is 27% below median its own 10-year median of 23.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi Jinbo Bio pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) is currently considered Possible Value Trap. The stock's GF Value™ is ¥235.87, compared to a current price of ¥113.97 — trading 51.7% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 16.96, which is 27% below median its 10-year median of 23.35 and 976.8% above the Biotechnology industry median of 1.58. Shanxi Jinbo Bio pharmaceutical Co's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982), the current Cyclically Adjusted PB Ratio is 16.96 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) Overvalued in 2026?
Based on GuruFocus' analysis, Shanxi Jinbo Bio pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥113.97 is trading 51.7% below its estimated GF Value™ of ¥235.87.
GuruFocus considers Shanxi Jinbo Bio pharmaceutical Co to be Possible Value Trap.
Key valuation signals for BJSE:920982:
Cyclically Adjusted PB Ratio: 16.96 (27% below median its 10-year median of 23.35)
GF Value™: ¥235.87 vs. price of ¥113.97 (51.7% below fair value)
Industry Position: 976.8% above the Biotechnology median (#621 of 680)
No single metric tells the full story. See the BJSE:920982 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanxi Jinbo Bio pharmaceutical Co Ltd is engaged in research & development, production and sales of various medical devices and functional skin care products with recombinant collagen products and anti-HPV biological protein products as the core.
77GF Score
Get the complete analysis for BJSE:920982
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920982 has been successfully added to your 
